ATLANTA, March 28, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Harmony Biosciences Holdings, Inc. (“Harmony Biosciences” or the “Company”) (NASDAQ: HRMY) complied with federal securities laws. On March 28, 2023, Scorpion Capital published a report alleging that twelve deaths occurred during foreign clinical trials of its drug, Wakix. Scorpion Capital further alleges that “explosive information was concealed from the FDA that would have prevented approval” of Wakix. Following this report, the price of the Company’s stock dropped.
If you purchased Harmony Biosciences stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/harmony-biosciences/ discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
- Star Equity Fund Calls on SVT Board to Conduct Strategic Review For ALL Assets - May 31, 2023
- Uncle Budd NYC Makes Historic Debut as New York’s First Black-Owned Cannabis Brand at CWCB Expo 2023 - May 31, 2023
- California Water Service Ranks Highest in the West Among Large Water Utilities in J.D. Power Residential Customer Satisfaction Study - May 31, 2023